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Multimodal action of Mas activation for systemic cancer cachexia therapy 
Cancer cachexia remains a largely intractable, deadly condition for patients with no 
approved, effective therapies. However, research progress over the past few decades 
demonstrates that cachexia is a disease with specific, targetable mechanisms. New work by 
Murphy and colleagues in this issue of Cancer Research suggests that activation of the 
alternative renin-angiotensin system with the non-peptide Mas receptor agonist AVE0991 
holds promise for reducing muscle wasting in cancer. Their cell studies demonstrate on-target 
activity in skeletal muscle cells, while their mouse results suggest potentially more important 
systemic effects. 
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Cachexia, extreme weight loss and muscle wasting, is most readily recognized when patients 
with late-stage cancer become disturbingly emaciated prior to death, but in reality, adipose and 
muscle loss are often detectable in the early stages of disease. Moreover, cachexia is often 
underdiagnosed and the magnitude of muscle loss under-appreciated due to the predominance 
of obesity, particularly among cancer patients in Western nations. Using quantitative imaging 
analysis, it is estimated the incidence of cachexia ranges from 15% to 85% across tumor types 
(1). However, regardless of tumor type, the majority of patients with late-stage disease suffer 
cachexia and some 25-30% of cancer patients are thought to die of cachexia, rather than other 
effects of the tumor (1). The low muscle mass, systemic inflammation, and dysmetabolism 
characteristic of cachexia also impair treatment response to surgery, radiation therapy, and 
chemotherapy. Inadequate to its impact, from 2004-2018 only 20 pharmacological clinical trials 
have been reported in cancer cachexia (2). Work over the past several decades has vastly 
increased the knowledge around the physiological, cellular, and molecular interactions leading 
to adipose and muscle wasting in cachexia, demonstrating that cachexia is not an inevitable 
consequence of cancer, but rather a disease condition with specific, targetable mechanisms.  
Tumors create metabolic and immune havoc, hijacking the body’s normal response to injury 
and inflammation. Cancer cells activate host defenses causing anorexia, malabsorption, 
reduced activity, asthenia, inefficient energy utilization, abnormalities in the innate and 
adaptive immune systems, and often persistent systemic inflammation. Such phenomena lead 
to progressive weight loss, regardless of conventional nutritional support. Thus, cachexia is a 
syndrome with multiple affected organ systems and a characteristic spectrum of symptoms (3). 
Nevertheless, consensus definitions of cancer cachexia specify degree of weight loss and/or 
skeletal muscle depletion as diagnostic criteria (4). Most cachexia research has focused on 
skeletal muscle wasting, due to its central role in mobility, function, respiration and 
metabolism, and due to the association of low muscle mass with mortality. Indeed, the 
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systemic effects of cancer ultimately produce muscle wasting through impaired anabolism, 
protein degradation, metabolic dysfunction, and blunted myogenesis. To date, specific 
interventions to increase muscle mass or block muscle wasting have prolonged life and function 
in mouse models of cancer cachexia, suggesting that saving muscle could improve survival and 
outcomes for patients with cachexia (1). 
 
Work by Murphy and colleagues in this issue of Cancer Research opens a new line of 
investigation by interrogating the alternative arm of the renin-angiotensin system (RAS) in 
cancer cachexia (5).  The RAS system was originally identified as a regulator of blood pressure 
and fluid balance but is now known to play a variety of roles in health and disease in multiple 
organ systems, including the brain, kidney, heart, adipose tissue, and skeletal muscle (6).  
Angiotensinogen is cleaved by renin to angiotensin I, and subsequently by angiotensin 
converting enzyme (ACE) to form angiotensin (Ang) II, which activates type 1 or type 2 
receptors (AT1R, AT2R). Ang II signaling increases sympathetic outflow and vasoconstriction, 
but also promotes fibrosis and oxidative stress. Ang-(1-7) can be generated from Ang I or Ang II 
by ACE2, and activates Mas (gene name Mas1), a member of the G protein-coupled receptor 
family. Ang-(1-7) and Mas generally oppose activities of Ang II and AT1 and AT2 receptors (6).  
Specificity in regulation of this pathway is provided in part by special and temporal differences 
in receptor and enzyme distribution. In skeletal muscle, it is well-established that Ang II 
signaling on AT1 can induce atrophy and fibrosis (7). Antagonism of this pathway either through 
Ang II inhibition or ACE2/Ang-(1-7)/Mas activation can lessen muscle atrophy and dysfunction 
in muscular dystrophy, disuse atrophy, and sepsis models (7).  
 
Herein, Murphy and colleagues show that Mas receptor expression is decreased in the muscle 
of mice and patients with cancer cachexia, while AT1R is increased. This result suggests a 
context of active classical RAS signaling and repressed alternative Ang-(1-7) signaling in 
cachexia. Furthermore, they show that in cultured muscle cells, Mas expression, Ang-(1-7) or 
the non-peptide Mas receptor agonist AVE0991 can block atrophy induced by serum starvation 
or by co-culture with cachexia-causing cancer cells, although neither has a hypertrophic effect 
in normal culture conditions. These results indicate that Mas activation can counter atrophy-
promoting pathways directly on muscle cells.  Some novel proteomic and miRNA studies 
included here point to potential muscle-specific mechanisms for further investigation. Finally, 
they show convincingly that AVE0991 can protect mice from cachexia induced by C26 colon 
carcinoma cells, demonstrated by the reduction in weight loss and muscle wasting as well as 
anorexia and activity decline that accompanies tumor growth in this model. 
 
Cachexia is a systemic condition assayed in mice, and the Murphy and colleagues study is a 
pharmacological study rather than one that employs muscle-specific genetic manipulation of 
the Mas pathway. Thus, it is impossible to separate effects of AVE0991 on muscle from effects 
on the RAS system in the tumor and other tissues. Moreover, the experimental design used co-
culture of C26 or Lewis Lung Carcinoma (LLC) cells with myotubes, raising the potential that 
even the in vitro effects of AVE0991 in cachexia conditions might be mediated through signaling 
on tumor cells. Indeed, the authors do not report muscle or plasma ligand levels to 
demonstrate that Ang II might be elevated or Ang-(1-7) limiting in cachexia and actually show 
that Mas receptor expression is reduced in muscle during cachexia. This leaves open the 
possibility that while AVE0991 might activate the remaining pool of protein and antagonize 
local Ang II signaling, it might also act on other organs important in cachexia and known to 
express Mas, including the brain, heart, vessels, tumor cells, tumor microenvironment, and 
immune cells (8). Such effects could include central effects on appetite regulation and activity, 
improvement in cardiovascular function, anti-inflammatory effects, and anti-tumor effects. 
Moreover, it is possible that the anti-tumor effects can be observed with any effective anti-
cachexia therapy; depriving the tumor of a rich source of lipids and amino acids could restrict 
tumor growth. The authors acknowledge these additional potential mechanisms, particularly 
the anti-tumor effects of AVE0991 and this sets the stage for further discovery. 
 
The implications of this study are exciting. Given its syndromic nature, the ideal anti-cachexia 
drug would target multiple drivers of muscle wasting—tumor, inflammation, metabolism—and 
not necessarily act only at the end-organ or myofiber (9). This might or might not require multi-
modal therapy given that known targets in cancer cachexia affect a range of biological 
processes, e.g. the cytokines Interleukin-6, GDF-15, and Activin (1). In addition, the ideal 
readout for efficacy is likely a compound metric of symptoms not reducible to a single primary 
endpoint of lean mass or grip strength (10). As such, AVE0991 or other Mas agonists in clinical 
development appear to be excellent candidates for testing in patients with cancer cachexia or 
in patients projected to experience cachexia. With 5-year survival rates for some cachexia-
associated cancers including pancreatic cancer and biliary cancers <9%, the bar should be 
correspondingly low to interrogate such new molecules and mechanisms in rigorously designed 
interventional trials that account for the systemic, multifactorial nature of this condition. 
 
 
References: 
 
 
1. Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. 
Nat Rev Dis Primers 2018;4:17105 
2. Advani SM, Advani PG, VonVille HM, Jafri SH. Pharmacological management of cachexia 
in adult cancer patients: a systematic review of clinical trials. BMC Cancer 2018;18:1174 
3. Zimmers TA, Fishel ML, Bonetto A. STAT3 in the systemic inflammation of cancer 
cachexia. Semin Cell Dev Biol 2016;54:28-41 
4. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and 
classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489-
95 
5. Murphy KT, Hossain MI, Swiderski K, Chee A, Naim T, Trieu J, et al. Mas receptor 
activation slows tumor growth and attenuates muscle wasting in cancer. Cancer Res 
2018 
6. Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, et al. The 
ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on 
Angiotensin-(1-7). Physiol Rev 2018;98:505-53 
7. Powers SK, Morton AB, Hyatt H, Hinkley MJ. The Renin-Angiotensin System and Skeletal 
Muscle. Exerc Sport Sci Rev 2018;46:205-14 
8. Argiles JM, Stemmler B, Lopez-Soriano FJ, Busquets S. Inter-tissue communication in 
cancer cachexia. Nat Rev Endocrinol 2018 
9. Arends J, Baracos V, Bertz H, Bozzetti F, Calder PC, Deutz NEP, et al. ESPEN expert group 
recommendations for action against cancer-related malnutrition. Clin Nutr 
2017;36:1187-96 
10. Le-Rademacher JG, Crawford J, Evans WJ, Jatoi A. Overcoming obstacles in the design of 
cancer anorexia/weight loss trials. Crit Rev Oncol Hematol 2017;117:30-7 
 
